睿知中国医院研究地图
候选清单

正在招募胰腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

ClinicalTrials.gov 上登记的一项胰腺癌开放试验。牵头方不是本站收录的医院;本站收录的 5 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 5

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  2. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  3. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  4. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  5. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06767813,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.

    入选标准第 3 条

  3. No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.

    入选标准第 5 条

    Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.

    排除标准第 2 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.

    入选标准第 6 条

  5. Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;

    入选标准第 4 条

  6. Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.

    排除标准第 1 条

  7. Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

    入选标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06767813,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Subjects must voluntarily participate in the study and sign the informed consent form.
  2. Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
  3. Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
  4. Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
  5. No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.
  7. Normal major organ function.
  8. Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

排除标准:Exclusion Criteria:

  1. Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
  2. Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
  3. Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
  4. Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.
  5. Arterial or venous thrombotic events within 6 months prior to the first dose.
  6. Active gastric or duodenal ulcers, perforations, persistent positive fecal occult blood tests, ulcerative colitis, or other gastrointestinal bleeding conditions within 6 months prior to the first dose; or other bleeding conditions as assessed by the investigator.
  7. Hepatitis B virus (HBV)-infected patients unable to adhere to consistent antiviral therapy, or Hepatitis C virus (HCV)-infected patients (positive for HCV Ab or HCV RNA) deemed unstable by the investigator or requiring continued antiviral therapy without consistent adherence.
  8. History of substance abuse involving psychotropic drugs that cannot be discontinued or presence of psychiatric disorders.
  9. Symptomatic interstitial lung disease or conditions likely to cause drug-induced lung toxicity or related pneumonitis.
  10. Presence of any severe and/or uncontrolled diseases.
  11. Histological or cytological confirmation of other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, or pancreatoblastoma.
  12. Tumors confirmed via imaging (CT or MRI) to have invaded major blood vessels, with the investigator deeming a high likelihood of fatal hemorrhage during the study.
  13. Tumors confirmed via imaging (CT or MRI) to have invaded the gastrointestinal tract, with a high risk of bleeding based on endoscopy and investigator assessment.
  14. Known central nervous system metastases and/or carcinomatous meningitis.
  15. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage, as assessed by the investigator.
  16. History of severe allergic reactions to biologic agents or known hypersensitivity to any component of TQB2868 injection.
  17. Chronic treatment with systemic corticosteroids or other immunosuppressive agents within 28 days prior to the first dose, and continued use of such medications within 2 weeks after the first dose.
  18. Receipt of live attenuated vaccines within 28 days prior to the first dose or planned administration of live attenuated vaccines during the study.
  19. Systemic therapy required within 2 years prior to the first dose for any condition. Alternative therapies are not considered systemic therapy.
  20. Participation in other clinical trials involving anti-tumor drugs within 28 days prior to the first dose.
  21. Any comorbidities or conditions deemed by the investigator to pose severe risks to the subject's safety or the completion of the study, or any other reasons rendering the subject unsuitable for enrollment.

引自 ClinicalTrials.gov, NCT06767813, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06767813,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06767813